Puma Biotechnology

Earnings Call

Commercial Update

May 5, 2022

nerlynx®
(neratinib) tablets

Puma Biotechnology

Forward-Looking Safe-Harbor Statement

This presentation contains forward-looking statements, including statements regarding commercialization of NERLYNX® and the potential indications and development of our drug candidates. All forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on our current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update these forward-looking statements except as required by law.

Puma Biotechnology

PUMA's Pharmacy and Distributor Network



~$41 Million net NERLYNX revenue in Q1’22



2,680 Ex-factory bottles were sold in Q1’22



Includes Commercial SP and SD

~62% of patients in Q1’22 started at a reduced dose* **



*Reduced dose defined as fewer than 6 pills per day

** FDA approved dose-escalation label supplement in June 2021

Rest of World Partnerships – Timelines

Region	Partner	Regulatory Approvals	Commercial Launches
Australia / SE Asia	Specialised Therapeutics	• 2019 – Ext. Adj. in Australia, Singapore • 2020 – Ext. Adj. in Brunei, Malaysia, New Zealand	• 2020 – Singapore • Q2 2021 – Malaysia • Q3 / Q4 2021 – Brunei, New Zealand
Israel	MEDISON	• 2020 – Approved in Ext. Adj. and mBC	• 2020 – Launched
Canada	Knight	• 2019 – Ext.. Adj. approved • Q2 2021 – mBC approved	• 2020 – Launched
Latin America	PINT PHARMA	• 2019 – Ext Adj in Argentina • 2020 – Ext. Adj in Chile, Ecuador • 2020 – mBC in Argentina • 2021 – Ext Adj and mBC in Peru; mBC in Chile • Q4 2021 – Ext. Adj. in Brazil • Q1 2022 – Ext. Adj. in Mexico	• 2020 – Argentina • Q2 2021 – Chile • Q4 2021 – Peru
Europe Greater China Middle East North and West Africa South Africa Turkey	Pierre Fabre	• 2019 – EMA approval • 2019 – Ext. Adj. in Hong Kong • 2020 – Ext. Adj. in China, Taiwan • Q4 2021 – mBC in Taiwan	• 2019 – Germany, UK, Austria • 2020 – Sweden, Finland, Scotland, Switzerland, Denmark • 2020 – Hong Kong • Q1 2021 – China (added to 2021 NRDL), Taiwan • Q1 2021 – Greece, Czech Republic • Q1 2022 – Ireland
South Korea	BIXINK THERAPEUTICS	• Q4 2021 – Ext. Adj. in S. Korea	• Q1 2022 – Launched

Puma Biotechnology

Earnings Call

Commercial Update

May 5, 2022

nerlynx®
(neratinib) tablets

Puma Biotechnology